Nuvilex Inc. (NASDAQ:PMCB) Short Interest Down 61.7% in August

Nuvilex Inc. (NASDAQ:PMCB) was the recipient of a large decrease in short interest during the month of August. As of August 31st, there was short interest totaling 79,793 shares, a decrease of 61.7% from the August 15th total of 208,161 shares. Based on an average trading volume of 91,412 shares, the days-to-cover ratio is currently 0.9 days. Approximately 0.8% of the company’s stock are sold short.

Nuvilex Trading Down 12.9%

Shares of Nuvilex stock traded down $0.06 on Monday, reaching $0.39. 579,387 shares of the company were exchanged, compared to its average volume of 88,737. The company has a market capitalization of $4.21 million, a price-to-earnings ratio of -0.13 and a beta of 0.66. Nuvilex has a one year low of $0.35 and a one year high of $1.51. The company has a 50-day moving average of $0.57 and a 200 day moving average of $0.68.

Nuvilex (NASDAQ:PMCB) last issued its earnings results on Monday, September 14th. The company reported ($0.54) earnings per share for the quarter.

Analysts Set New Price Targets

Separately, Weiss Ratings cut shares of Nuvilex from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, September 2nd. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, Nuvilex has a consensus rating of “Sell”.

Nuvilex Company Profile

PharmaCyte Biotech, Inc, a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. The company develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; and license agreements with SG Austria Pte.